Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial
El ensayo piloto PEARL es un ensayo abierto de fase II. Los participantes recibirán una única dosis alta (25 mg) de psilocibina en el contexto de la terapia existencial, de apego y relacional asistida por psilocibina (PEARL).
- Status
- active
- Phase
- Phase 2
- Institution
- University Health Network, Toronto
- Principal investigator
- Sarah Hales, MD
- Start date
- 2024-06-06
- End date
- 2026-12-15
- Registry ID
- NCT06416085
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.